The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
Stopped Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08.
Conditions
Interventions
- DRUG: Insulin glargine injection
- DRUG: metformin
- DRUG: Placebo pill
Sponsor
Brigham and Women's Hospital
Collaborators